Aripiprazole: A novel atypical antipsychotic acts as stabilizer of the dopamine system;Aripiprazol - Ein partieller dopamin-agonist als neues antipsychotikum

Psychopharmakotherapie

Volumn 13, Issue 2, 2006, Pages 49-54

  Klein, Nikolas ^a,b   Wallner, Helene ^a,b   Kasper, Siegfried ^a,b  

^a Klinische Abteilung für Allgemeine Psychiatrie ^*

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Aripiprazole; Bipolar disorder; Dopamine stabilizer; Partial agonist; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; PLACEBO;

BIPOLAR DISORDER; CLINICAL TRIAL; DOPAMINERGIC SYSTEM; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; REVIEW; SCHIZOPHRENIA;

EID: 33645918588     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. 2 receptors. J Pharmacol Exp Ther 2002;302:381-9.
2. Carlsson ML, Carlsson A, Nilsson M. Schizophrenia: from dopamine to glutamate and back. Curr Med Chem 2004;11:267-77.
3. Casey DE, Carson WH, Saha AR, Liebeskind A, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003;166:391-9.
4. FDA. Medical Reviews Application Number 21-436. In: http://www.fda.gov/ cder/foi/nda/2002/21-436_Abilify.htm; 2002.
5. Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 2003;60:974-7.
6. 2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 1997;321:105-11.
7. Inoue T, Domae M, Yamada K, Furukawa T. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4- dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 1996;277:137-43.
8. 1A receptor. Eur J Pharmacol 2002;441:137-40.
9. Kane JM, Carson WH, Saha AR, McQuade RD, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-71.
10. Kasper S. How much do novel antipsychotics benefit the patients? Int Clin Psychopharmacol 1998;13(Suppl 3):S71-7.
11. Kasper S, Lerman MN, McQuade RD, Saha A, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6:325-37.
12. Kasper S, Resinger E. Cognitive effects and antipsychotic treatment. Psychoneuroendocrinology 2003;28(Suppl 1):27-38.
13. Kasper SL, Lehofer M (Hrsg.). Schizophrenie - Medikamentöse Therapie. State of the Art 2003. 2. Aufl. CliniCum 2003; Sonderausgabe Mai 2003.
14. Keck PE Jr., Marcus R, Tourkodimitris S, Ali M. et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-8.
15. 2 receptor antagonistic activity. J Pharmacol Exp Ther 1995;274:329-36.
16. Lawler CP, Prioleau C, Lewis MM, Mak C, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999;20:612-27.
17. Lyseng-Williamson KA, Perry CM. Aripiprazole: in acute mania associated with bipolar I disorder. CNS Drugs 2004;18:367-76.
18. Mallikaarjun S, Salazar D, Bramer SL, Gao X, et al. Effects of time of dosing and food on aripiprazole pharmacokinetics. APA 2003.
19. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004;44:179-87.
20. Marder SR, McQuade RD, Stock E, Kaplita S, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-36.
21. McQuade RD, Burris KD, Jordan S. Aripiprazole: a dopamine-serotonin system stabilizer. Int J Neuropsychopharmacol 2002;5(Suppl 1): S176.
22. Meltzer HY. Outcome in schizophrenia: beyond symptom reduction. J Clin Psychiatry 1999;60(Suppl 3):3-7.
23. Pigott TA, Carson WH, Saha AR, Torbeyns AF, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-56.
24. Potkin SG, Saha AR, Kujawa MJ, Carson WH, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-90.
25. Riedel M, Strassnig M, Kühn KU, Müller N, et al. Aripiprazol. Psychopharmakotherapie 2003;10:46-55.
26. Sajatovic M. Treatment for mood and anxiety disorders: quetiapine and aripiprazole. Curr Psychiatry Rep 2003;5:320-6.
27. Shapiro DA, Renock S, Arrington E, Chiodo LA, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400-11.
28. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics. Part 1: "Goldilocks" actions at dopamine receptors. J Clin Psychiatry 2001;62:841-2.
29. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics. Part 2: illustrating their mechanism of action. J Clin Psychiatry 2001;62:923-4.
30. Tamminga CA, Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord 2002;1:141-7.
31. WHO. Schizophrenia. http://www.who.int/mental_health/management/ schizophrenia/en/;2004(June 21).